Ethyl biscoumacetate is a courmarin that is used as an anticoagulant. It has actions similar to those of Warfarin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p226)
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Apixaban | Apixaban may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Dabigatran etexilate | Dabigatran etexilate may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Dasatinib | The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Ethyl biscoumacetate. |
| Deferasirox | The risk or severity of gastrointestinal bleeding can be increased when Ethyl biscoumacetate is combined with Deferasirox. |
| Ursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Ethyl biscoumacetate is combined with Ursodeoxycholic acid. |
| Glycochenodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Ethyl biscoumacetate is combined with Glycochenodeoxycholic Acid. |
| Cholic Acid | The risk or severity of bleeding and bruising can be increased when Ethyl biscoumacetate is combined with Cholic Acid. |
| Glycocholic acid | The risk or severity of bleeding and bruising can be increased when Ethyl biscoumacetate is combined with Glycocholic acid. |
| Deoxycholic acid | The risk or severity of bleeding and bruising can be increased when Ethyl biscoumacetate is combined with Deoxycholic acid. |
| Taurocholic acid | The risk or severity of bleeding and bruising can be increased when Ethyl biscoumacetate is combined with Taurocholic acid. |
| Obeticholic acid | The risk or severity of bleeding and bruising can be increased when Ethyl biscoumacetate is combined with Obeticholic acid. |
| Chenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Ethyl biscoumacetate is combined with Chenodeoxycholic acid. |
| Taurochenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Ethyl biscoumacetate is combined with Taurochenodeoxycholic acid. |
| Tauroursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Ethyl biscoumacetate is combined with Tauroursodeoxycholic acid. |
| Bamet-UD2 | The risk or severity of bleeding and bruising can be increased when Ethyl biscoumacetate is combined with Bamet-UD2. |
| Dehydrocholic acid | The risk or severity of bleeding and bruising can be increased when Ethyl biscoumacetate is combined with Dehydrocholic acid. |
| Hyodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Ethyl biscoumacetate is combined with Hyodeoxycholic Acid. |
| Edoxaban | The risk or severity of bleeding can be increased when Edoxaban is combined with Ethyl biscoumacetate. |
| Ibrutinib | The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Ethyl biscoumacetate. |
| Obinutuzumab | The risk or severity of bleeding and hemorrhage can be increased when Ethyl biscoumacetate is combined with Obinutuzumab. |
| Rivaroxaban | Ethyl biscoumacetate may increase the anticoagulant activities of Rivaroxaban. |
| Sugammadex | The risk or severity of bleeding and hemorrhage can be increased when Ethyl biscoumacetate is combined with Sugammadex. |
| Tibolone | Tibolone may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Tipranavir | The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Ethyl biscoumacetate. |
| Urokinase | Urokinase may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Vitamin E | Vitamin E may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Vorapaxar | The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Ethyl biscoumacetate. |
| Gemcitabine | The therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Gemcitabine. |
| Flunisolide | Flunisolide may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Beclomethasone dipropionate | Beclomethasone dipropionate may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Betamethasone | Betamethasone may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Fluticasone propionate | Fluticasone propionate may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Fluocinolone acetonide | Fluocinolone acetonide may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Prednisone | Prednisone may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Fludrocortisone | Fludrocortisone may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Hydrocortisone | Hydrocortisone may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Prednisolone | Prednisolone may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Methylprednisolone | Methylprednisolone may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Trilostane | Trilostane may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Budesonide | Budesonide may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Dexamethasone | Dexamethasone may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Corticotropin | Corticotropin may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Cortisone acetate | Cortisone acetate may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Paramethasone | Paramethasone may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Ciclesonide | Ciclesonide may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Aldosterone | Aldosterone may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Fluticasone furoate | Fluticasone furoate may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Fluprednidene | Fluprednidene may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Tixocortol | Tixocortol may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Fluprednisolone | Fluprednisolone may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Meprednisone | Meprednisone may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Dexamethasone isonicotinate | Dexamethasone isonicotinate may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Melengestrol | Melengestrol may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Deflazacort | Deflazacort may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Cortivazol | Cortivazol may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Prednylidene | Prednylidene may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Fluocortin | Fluocortin may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Fluperolone | Fluperolone may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Cloprednol | Cloprednol may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Fluclorolone | Fluclorolone may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Fluticasone | Fluticasone may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Mometasone furoate | Mometasone furoate may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Hydrocortisone acetate | Hydrocortisone acetate may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Hydrocortisone cypionate | Hydrocortisone cypionate may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Hydrocortisone succinate | Hydrocortisone succinate may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Prednisolone phosphate | Prednisolone phosphate may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Prednisolone hemisuccinate | Prednisolone hemisuccinate may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Methylprednisolone hemisuccinate | Methylprednisolone hemisuccinate may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Prednisone acetate | Prednisone acetate may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Clocortolone acetate | Clocortolone acetate may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Melengestrol acetate | Melengestrol acetate may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Betamethasone phosphate | Betamethasone phosphate may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Cortisone | Cortisone may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Clobetasol propionate | Clobetasol propionate may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Fluocinonide | Fluocinonide may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Hydrocortisone butyrate | Hydrocortisone butyrate may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Desoximetasone | Desoximetasone may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Mometasone | Mometasone may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Fluocortolone | Fluocortolone may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Prednisolone acetate | Prednisolone acetate may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Fluorometholone | Fluorometholone may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Difluocortolone | Difluocortolone may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Flumethasone | Flumethasone may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Methylprednisolone aceponate | Methylprednisolone aceponate may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Erlotinib | The serum concentration of Ethyl biscoumacetate can be increased when it is combined with Erlotinib. |
| Acetaminophen | Acetaminophen may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Allopurinol | The risk or severity of bleeding can be increased when Allopurinol is combined with Ethyl biscoumacetate. |
| Azathioprine | The therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Azathioprine. |
| Chloral hydrate | The protein binding of Ethyl biscoumacetate can be decreased when combined with Chloral hydrate. |
| Methylphenidate | The metabolism of Ethyl biscoumacetate can be decreased when combined with Methylphenidate. |
| Disulfiram | Disulfiram may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Etacrynic acid | The protein binding of Ethyl biscoumacetate can be decreased when combined with Etacrynic acid. |
| Ethotoin | The therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Ethotoin. |
| Etoposide | The therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Etoposide. |
| Exenatide | Exenatide can cause an increase in the absorption of Ethyl biscoumacetate resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Gefitinib | Gefitinib may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Ginkgo biloba | Ginkgo biloba may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Glutethimide | The therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Glutethimide. |
| Ifosfamide | The risk or severity of bleeding can be increased when Ifosfamide is combined with Ethyl biscoumacetate. |
| Leflunomide | The therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Leflunomide. |